- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05095688
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
October 15, 2021 updated by: Dongying Zhang, Chongqing Medical University
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in Heart Failure With Preserved Ejection Fraction(HFpEF)
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis.
Studies have found that hypertension and obesity are respectively associated with increased arterial stiffness.
However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.
Study Overview
Status
Recruiting
Detailed Description
Before the 21st century, Heart failure with preserved ejection fraction (HFpEF) was considered as a disease with simple diastolic dysfunction, but after the 21st century, HFpEF was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis.
Other studies have found that hypertension and obesity are respectively associated with increased arterial stiffness.
However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chongqing, China, 400000
- Recruiting
- The First Affiliated Hospital of Chongqing Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Heart failure patients with preserved ejection fraction (HFpEF)
Description
Inclusion Criteria:
- Adult aged >=18years old;
- Diagnosed with HFpEF.
Diagnostic criteria including:
- left ventricular ejection fraction ≥50%;
- with the symptoms and/or signs of heart failure;
- BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL;
- at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction
Exclusion Criteria:
- LVEF less than 45% at any time;
- Severe liver failure; 3/Other causes of shortness of breath, such as severe pulmonary disease or severe chronic obstructive pulmonary disease;
4.Primary pulmonary hypertension; 5.Severe valvular disease of the left heart; 6.Chronically bedridden or incapacitated; 7.Age <18 years old.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arterial stiffness
Time Frame: 1 day after admission
|
The baPWV(cm/s) of HFpEF patients
|
1 day after admission
|
|
adipose tissue distribution
Time Frame: 1 day after admission
|
The visceral fat area(cm^2) in HFpEF patients
|
1 day after admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 21, 2020
Primary Completion (Anticipated)
December 31, 2021
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
October 11, 2020
First Submitted That Met QC Criteria
October 15, 2021
First Posted (Actual)
October 27, 2021
Study Record Updates
Last Update Posted (Actual)
October 27, 2021
Last Update Submitted That Met QC Criteria
October 15, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-09-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipid Disorder
-
Johns Hopkins UniversityVAP Diagnostics LabActive, not recruiting
-
University of PennsylvaniaCompletedBlood Pressure Check (Hypertension Screening) | Cholesterol Test (Lipid Disorder Screening)United States
-
The Miriam HospitalRecruitingLipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid DisordersLipid DisordersUnited States
-
University of OsloNorwegian Institute of Public Health; Ullevaal University Hospital; Hormone Laboratory... and other collaboratorsUnknown
-
Université de SherbrookeHospices Civils de LyonCompleted
-
Merck Sharp & Dohme LLCCompletedLipid Metabolism Disorder
-
University of PennsylvaniaAmarin Pharma Inc.CompletedDyslipidemias | Lipid Disorder | Triglycerides HighUnited States
-
Olga Ramich (formerly Pivovarova)Charite University, Berlin, GermanyRecruitingChronodisruption | Glucose and Lipid Metabolism | Shift Work DisorderGermany
-
National Research Council, SpainCompleted
-
Zydus Lifesciences LimitedTerminatedObesity | Lipid DisordersIndia